Medicare’s Wegovy Expansion and Oral Wegovy’s Rapid Uptake: The Catalysts Novo Nordisk’s Critics Are Overlooking
Published on 06/19/2026 at 07:33 | Redaktion boerse-global.de
Come July 2026, millions of US seniors will gain affordable access to Wegovy for the first time. Under the Medicare Bridge Program, eligible patients will pay just $50 a month for the blockbuster weight-loss drug. Novo Nordisk estimates 3.4 million beneficiaries will qualify in the first six months alone. It’s a structural shift that could unlock a whole new patient pool – and it’s barely registering in the stock’s depressed price.
The share price tells a grim story. Over the past twelve months, Novo Nordisk has shed roughly 42% of its value, wiping away about €75 billion in market capitalisation. From its 52?week high of €65.20, the precise retreat stands at 42.19%, with the stock now changing hands near €37.70. The sceptics have plenty of ammunition: Eli Lilly has seized roughly 60% of the GLP?1 market, leaving Novo with just 40%. The company itself warns of a 4% to 12% drop in revenue this year on a comparable?currency basis.
But the bear case is already baked into the price. The stock trades nearly 9% below its 200?day moving average of €41.23, and the relative strength index offers a split verdict – one reading puts it at 50.7, another at 51.2, both hugging the neutral zone. Neither panic nor euphoria dominates. What is not yet priced in is the quiet revolution under way in the oral segment.
The Wegovy pill launched in January and has already surpassed one million patients. By April, weekly prescriptions were running at over 200,000 – the fastest start for any weight?loss therapy in US history. Chief executive Mike Doustdar calls it a “turnaround situation”, and the numbers back him up: the oral version now captures 65% of all new prescriptions in the US. It is pulling in patients who shun injections and newcomers without prior access to GLP?1 drugs. After the day of first?quarter earnings, the stock jumped 3% as the pill’s performance offset sluggish injection sales.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The oral launch overshadowed another setback. In February, Novo revealed that its next?generation candidate CagriSema delivered a 23% weight loss after 84 weeks, trailing Eli Lilly’s Zepbound at 25.5%. The market had expected equivalence, and the shares dropped 16% in a single session. Yet nearly 51% of CagriSema patients achieved a BMI under 30, and the company has already filed for FDA approval, with a decision expected by the end of 2026. The European Medicines Agency, meanwhile, has recommended marketing authorisation for the Wegovy pill, clearing the way for an ex?US rollout in the second half.
Beyond the immediate product cycle, the pipeline is gathering momentum. Novo has initiated AMAZE, a phase?3 programme for its oral candidate Zenagamtid in obesity. And while first?quarter total revenue slipped 4% year on year to 70.1 billion Danish kroner, the obesity?care segment posted a 22% advance on a comparable?currency basis. The volume story remains intact even as pricing pressure squeezes the US business.
The recent technical picture offers a glimmer of hope. The 50?day moving average of €36.85 sits below the current price for the first time in months – not a full?blown trend reversal, but a tentative stabilisation. The distance to the 52?week low of €30.25 is now 24.6%, suggesting the worst may already be in the rear?view mirror.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
None of this makes Novo Nordisk an easy hold. The bears have real arguments – pricing headwinds, market share losses, a management team that labels 2026 a trough year. But those arguments are well understood and widely discounted. What is still largely ignored is a pill that is rewriting the rules of the obesity market, a Medicare programme that opens the door to millions of seniors, and an international expansion that has not yet begun. For investors willing to look past the next few quarters, the risk?reward calculus is shifting from fear to patience.
Ad
Novo Nordisk Stock: New Analysis - 19 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
